Navigation Links
Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
Date:3/5/2013

Geneva, Switzerland (PRWEB) March 05, 2013

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that the results from Company’s internal drug discovery platform R&D program have been published in Metabolic Engineering(1).

Publication Abstract
“CHO cell engineering to prevent polypeptide aggregation and improve therapeutic protein secretion”
The ability to efficiently produce recombinant proteins in a secreted form is highly desirable and cultured mammalian cells such as CHO cells have become the preferred host as they secrete proteins with human-like post-translational modifications. However, attempts to express high levels of particular proteins in CHO cells may consistently result in low yields, even for non-engineered proteins such as immunoglobulins. In this study, we identified the responsible faulty step at the stage of translational arrest, translocation and early processing for such a ‘‘difficult-to-express’’ immunoglobulin, resulting in improper cleavage of the light chain and its precipitation in an insoluble cellular fraction unable to contribute to immunoglobulin assembly. We further show that proper processing and secretion were restored by over-expressing human signal receptor protein SRP14 and other components of the secretion pathway. This allowed the expression of the difficult-to-express protein to high yields, and it also increased the production of an easy-to-express protein. Our results demonstrate that components of the secretory and processing pathways can be limiting, and that engineering of the secretory pathway may be used to improve the secretion efficiency of therapeutic proteins from CHO cells.

(1) The full article can be found online at http://www.sciencedirect.com/science/article/pii/S1096717613000025

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and morestable expression of recombinant proteins.

Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/metabolic_engineering/therapeutic_proteins/prweb10495971.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. BlowMeCool Inc. Announces a New Affiliate Program for Organizations Promoting Women’s Health & Wellness
2. Schuylkill Medical Associates LLC Announces Job Opening for a House Call Physician
3. VetWebsites (Websites for Veterinarians) Announces Partnership with VetsMyWay to Offer Website Marketing For Veterinarians
4. S.T.A.R. Clinic Announces William Henry as Keynote Speaker at Spring Clinic
5. MinuteHound Announces Monthly Price Plan That Fits Any Business's Budget
6. WeightWise Bariatric Program Announces New Dietician
7. Glidewell Laboratories Announces Customized Implant Component Stocking Inventory
8. The American Cancer Society Announces the Pinecrest Relay For Life Movement Goes Green
9. FileHold Systems Announces: Spanish Language Pack for FileHold Document Management software is now a Standard Feature
10. ACRM
11. American Congress of Rehabilitation Medicine Announces Co-Editors-in-Chief of Archives of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... first-quality education and high-level training standards to an international multidisciplinary group of healthcare ... problems. As a way to further its mission at the grassroots level, iaedp ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently ... Area counties for 2017. Almost 1,000 nominations were submitted and a little over ... Results were announced the magazine’s January 2017 issue . , Under the ...
(Date:1/14/2017)... ... 2017 , ... According to a December 9 article ... the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern California based ... linked to a Mediterranean diet are only some of the many reasons that ...
(Date:1/13/2017)... ... , ... A January 10 article in the Daily Star on ... with an emphasis on some new techniques that the publication says are becoming more ... casually to his patients and colleagues as Dr. J, comments that the best plastic ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... 2017 Stock-Callers is currently reviewing the ... (NASDAQ: WMGI ), Varian Medical Systems Inc. (NYSE: ... MDXG ), and NuVasive Inc. (NASDAQ: NUVA ). ... to a negative finish on Thursday, January 12 th , ... while shares of health care companies in the S&P 500 ...
(Date:1/13/2017)... , January 13, 2017 ... "Transfection Reagents and Equipment Market by Method (Biochemical ... Application (Biomedical, Protein Production), End User - Global ... studies the global market from 2016 to 2021. ... Billion by 2021 from USD 715.4 Million in ...
(Date:1/13/2017)... 13, 2017 Wichita Laser Clinic ... treatments to Wichita, Kansas featuring ... treatments for skin rejuvenation, getting rid of unwanted tattoos, ... vascular lesions. "Since being in the aesthetics ... Wichita for laser tattoo removal and ...
Breaking Medicine Technology: